Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | YES1 | P07947 | 7/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 7/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 5/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | EPHA4 | P54764 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366448 | 1.00 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| Hydrochloric Acid SCHEMBL4268361 | 0.99 | SRC (0.98) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL15095269 | 0.92 | SRC (0.86) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4272173 | 0.91 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4265021 | 0.91 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4275780 | 0.89 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4272203 | 0.89 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4264210 | 0.89 | SRC (0.85) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL12198200 | 0.88 | SRC (0.80) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL231130 | 0.88 | SRC (0.78) | SRCABL1YES1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12268715-B2 | Method for producing biological tissue-like structure | Orizuru Therapeutics, Inc. (JP) | 2025-04-08 | — | — | US | disclosed |
| CN-112867787-B | Insulin producing cells | 千纸鹤治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240318141-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-112313327-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| EP-4293105-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022172960-A1 | MATURATION AGENT | オリヅルセラピューティクス株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885YES1 237/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885YES1 237/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885YES1 237/4885 |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | AQP3, AQP1, AQP4 | SRC 4062/4885ABL1 4620/4885YES1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.